Association of asthma-related risk factors and lung function parameters to recurrent wheeze
| OR | 95% CI | |
| Lifetime asthma | 15.65 | 8.91 to 27.50 |
| Current asthma | 21.0 | 9.62 to 45.84 |
| Lifetime AR | 1.94 | 1.26 to 2.99 |
| Current AR | 2.29 | 1.46 to 3.58 |
| Lifetime AD | 1.71 | 1.13 to 2.57 |
| Current AD | 1.27 | 0.76 to 2.14 |
| Lifetime ER visit due to wheezing | 3.30 | 1.63 to 6.67 |
| Lifetime admission due to wheezing | 1.91 | 0.98 to 3.71 |
| Current ER visit due to wheezing | 2.61 | 0.71 to 9.54 |
| Current admission due to wheezing | 6.17 | 1.29 to 29.38 |
| Atopic sensitisation | 1.56 | 0.81 to 2.98 |
| Dose–response slope | 0.96 | 0.44 to 2.11 |
| Positive AHR | 1.68 | 0.61 to 4.66 |
| FEV1 (% predicted) | 0.98 | 0.96 to 0.99 |
| FVC (% predicted) | 0.99 | 0.97 to 1.01 |
| FEV1/FVC (%) | 0.96 | 0.92 to 0.99 |
| FEF25%–75% (% predicted) | 0.98 | 0.96 to 0.99 |
| Change of FEV1 after bronchodilator | 1.02 | 0.99 to 1.04 |
| eNO (ppb) | 1.05 | 1.01 to 1.10 |
| logTEC (/µL) | 1.31 | 0.97 to 1.74 |
| logIgE | 1.13 | 0.94 to 1.35 |
All values are adjusted for age, sex, height and weight.
AD, atopic dermatitis; AHR, airway hyper-reactivity; AR, allergic rhinitis; eNO, exhaled nitric oxide; ER, emergency room; FEF25%–75%, mid-forced expiratory flow; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; logIgE, logarithmic transformation of IgE; logTEC, logarithmic transformation of blood total eosinophil count.